Concepts and clinical trials of dose-dense chemotherapy for breast cancer

Clinical Breast Cancer

Volumn 6, Issue 5, 2005, Pages 402-411

  Orzano, Jennifer A ^a   Swain, Sandra M ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NONE   (United States)

Author keywords

Doxorubicin; Metronomic schedule; Sequential therapy; Taxanes; Tumor kinetics

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PACLITAXEL; PLACEBO; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; AMENORRHEA; ANEMIA; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CARDIOMYOPATHY; CARDIOTOXICITY; CLINICAL TRIAL; COGNITIVE DEFECT; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG SENSITIVITY; DRUG TOLERABILITY; ERYTHROCYTE TRANSFUSION; FEBRILE NEUTROPENIA; GRANULOCYTOPENIA; HUMAN; MASTECTOMY; MATHEMATICAL MODEL; MYELODYSPLASTIC SYNDROME; NAIL DISEASE; NEUROTOXICITY; NONHUMAN; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SKIN TOXICITY; STATISTICAL SIGNIFICANCE; VOMITING;

EID: 30544448634     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2005.n.044     Document Type: Review

References (64)

1. Jemal A, Murray T, Ward A, et al. Cancer statistics, 2005 [published erratum in CA Cancer J Clin 2005; 55:259]. CA Cancer J Clin 2005; 55:10-30.
2. Cole BF, Gelber RD, Gelber S, et al. Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis. Lancet 2001; 358:277-286.
3. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup trial C9741/Cancer and Leukemia Group B trial 9741 [published erratum in J Clin Oncol 2003; 21:2226]. J Clin Oncol 2003; 21:1431-1439.
4. Skipper HE. Kinetics of mammary tumor cell growth and implications for therapy. Cancer 1971; 28:1479-1499.
5. Surbone A, Gilewski TA, Norton L, et al. Cytokinetics and principles of chemotherapy. In: Holland JF, Frei E III, Bast RC Jr, et al, eds. Cancer Medicine. 5th ed. Hamilton, ON: BC Decker; 2000.
6. Norton L. A Gonipertzian model of human breast cancer growth. Cancer Res 1988; 48:7067-7071.
7. Norton L, Simon R. The Nortou-Simon hypothesis revisited. Cancer Treat Rep 1986; 70:163-169.
8. Norton L. Theoretical concepts and the emerging role of taxanes in adjuvant therapy. Oncologist 2001; 6:30-35.
9. Hryniuk WM, Levine MN. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 1986; 4:1162-1170.
10. Hryniuk WM. Average relative dose intensity and the impact on design of clinical trials. Semin Oncol 1987; 14:65-74.
11. Bonadonna G, Zambetti M, Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. JAMA 1995; 273:542-547.
12. Kerbel R. Inhibition of tumor angiogenesis as a strategy to circumvent adquired resistance to anti-cancer therapeutic agents. Bioessays 1991; 13:31-36.
13. Norton L. Kinetic concepts in the systemic drug therapy of breast cancer. Semin Oncol 1999; 26:11-20.
14. Bonadonna G, Zambetti M, Moliterni A, et al. Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and fluorouracil in operable breast cancer. J Clin Oncol 2004; 22:1614-1620.
15. Haskell CM, Green SJ, Sledge GW Jr, et al. Phase III comparison of adjuvant high-dose doxorubicin plus cyclophosphamide (AC) versus sequential doxorubicin followed by cyclophosphamide (A->C) in breast cancer patients with 0-3 positive nodes (Intergroup 0137). Proc Am Soc Clin Oncol 2002; 21:36a (Abstract #142).
16. Venturini M, Aitini E, Del Mastro L, et al. Phase III adjuvant trial comparing standard versus accelerated FEC regimen in early breast cancer patients. Results from GONO - MIG1 study. Breast Cancer Res Treat 2003; 82(suppl):9 (Abstract #12).
17. Therasse P, Mauriac L, Welnicka-Jaskiewicz M, et al. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study. J Clin Oncol 2003; 21:843-850.
18. Miller KD, McCaskill-Stevens W, Sisk J, et al. Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: a randomized pilot trial of the Hoosier Oncology Group. J Clin Oncol 1999; 17:3033-3037.
19. Jackisch C, von Minckwitz G, Eidtmann H, et al. Dose-dense biweekly doxorubicin/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/docetaxel in operable breast cancer: second interim analysis. Presented at the 27th Annual San Antonio Breast Cancer Symposium; December 8-11, 2003; San Antonio, TX.
20. Hudis C, Fornier M, Riccio L, et al. 5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: a phase II study. J Clin Oncol 1999; 17:1118.
21. Fountzilas G, Nicolaides C, Aravantinos G, et al. Dose-dense adjuvant chemotherapy with epirubicin monotherapy in patients with operable breast cancer and >/=10 positive axillary lymph nodes. A feasible study. Oncology 1998; 55:508-512.
22. Baldini E, Gardin G, Giannessi PG, et al. Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: a randomized phase III trial in locally advanced breast cancer. Ann Oncol 2003; 14:227-232.
23. Marchetti P, Urien S, Cappellini GA, et al. Weekly administration of paclitaxel: theoretical and clinical basis. Crit Rev Oncol Hematol 2002; 44(suppl):S3-S13.
24. Olmsted JB, Borisy GG. Characterization of microtubule assembly in porcine brain extracts by viscometry. Biochem 1973; 12:4282-4289.
25. Moos PJ, Fitzpatrick FA. Taxane-mediated gene induction is independent of microtubule stabilization: induction of transcription regulators and enzymes that modulate inflammation and apoptosis. Proc Natl Acad Sci U S A 1998; 95:3896-3901.
26. Lau DH, Xue L, Young LJ, et al. Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. Cancer Biother Radiopharm 1999; 14:31-36.
27. Green MC, Buzdar AU, Smith T, et al. Weekly (wkly) paclitaxel (P) followed by FAC as primary systemic chemotherapy (PSC) of operable breast cancer improves pathologic complete remission (pCR) rates when compared to every 3-week (Q 3 wk) paclitaxel therapy (tx) followed by FAC. Final results of a prospective phase III randomized trial. Proc Am Soc Clin Oncol 2002; 21:35a (Abstract #135).
28. Lavelle F, Bissery MC, Combeau C, et al. Preclinical evaluation of docetaxel (Taxotere). Semin Oncol 1995; 22(2 suppl 4):3-16.
29. Crown J. Docetaxel: overview of an active drug for breast cancer. Oncologist 2001; 6(suppl 3):1-4.
30. Ferreira Filho AF, Crown J, Cardoso F et al. 3-year results of docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer: a pilot study. Anticancer Res 2002; 22:2471-2476.
31. Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001; 19:2865-2874.
32. Leyland-Jones B, O'Shaughnessy JA. Erythropoietin as a critical component of breast cancer therapy: survival, synergistic, and cognitive applications. Semin Oncol 2003; 30(5 suppl 16):174-84.
33. Acs G, Acs P, Beckwith SM, et al. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 2001; 61:3561-3565.
34. Acs G, Zhang PJ, Rebbeck TR, et al. Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma. Cancer 2002; 95:969-981.
35. Möbus VJ, Untch M, Du Bois A, et al. Dose-dense sequential chemotherapy with epirubicin (E), paclitaxel (T), and cyclophosphamdie (C) (ETC) is superior to conventional dosed chemotherapy in high-risk breast cancer patients (>4 +LN). First results of an AGO-trial. J Clin Oncol 2004; 22:513.
36. Leyland-Jones B; BEST Investigators and Study Group. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003; 4:459-460.
37. Smith RE, Bryant J, DeCillis A, et al. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol 2003; 21:1195-1204.
38. Tallman MS, Gray R, Bennett JM, et al. Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: the Eastern Cooperative Oncology Group experience. J Clin Oncol 1995; 13:1557-1563.
39. Curtis RE, Boice JD Jr, Stovall M, et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 1992; 326:1745-1775.
40. Hortobagyi G. Adjuvant therapy for breast cancer. Ann Review Med 2000; 51:377-392.
41. Brodsky RA, Bedi A, Jones RJ. Are growth factors leukemogenic? Leukemia 1996; 10:175-177.
42. Relling MV, Boyett JM, Blanco JG, et al. Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood 2003; 101:3862-3867.
43. Theodoulou M, Seidman AD. Cardiac effects of adjuvant therapy for early breast cancer. Semin Oncol 2003; 30:730-739.
44. Doroshow JH, Locker GY, Myers CE. Enzymatic defenses of the mouse heart against reactive oxygen metabolites: Alterations produced by doxorubicin. J Clin Invest 1980; 65:128-135.
45. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91:710-717.
46. Lefrak EA, Pitha J, Rosenheim S, et al. A clinicopathologic analysis of adriamycin toxicity. Cancer 1973; 32:302-314.
47. Torti FM, Bristow MR, Howes AE, et al. Rduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann Intern Med 1983; 99:745-749.
48. Weiss AJ, Metter GE, Fletcher WS, et al. Studies on adriamycin using weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity. Cancer Treat Rep 1976; 60:813-822.
49. Legha SS, Benjamin RS, Mackay B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982; 96:133-139.
50. Steinherz LJ, Steinherz PG, Tan CT, et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991; 266:1672-1677.
51. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003; 97:2869-2879.
52. van Dam F, Schagen S, Muller M, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 1998; 90:210-218.
53. Ganz P. Cognitive dysfunction following adjuvant treatment of breast cancer: a new dose-limiting toxic effect? J Natl Cancer Inst 1998; 90:182-183.
54. Ganz PA, Kwan L, Stanton AL, et al. Quality of life at the end of primary treatment of breast cancer: first results from the Moving Beyond Cancer randomized trial. J Natl Cancer Inst 2004; 96:376-387.
55. Piccart-Gebhart MJ. Mathematics and oncology: a match for life? J Clin Oncol 2003; 21:1425-1428.
56. Atkins CD. Dose-dense chemotherapy as adjuvant treatment for breast cancer. J Clin Oncol 2004; 22:749-780.
57. Stearns V, Singh B, Tsangaris T, et al. A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer. Clin Cancer Res 2003; 9:124-133.
58. Petit T, Wilt M, Velten M, et al. Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer 2004; 40:205-211.
59. Colleoni M, Viale G, Zahrieh D, et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res 2004; 10:6622-6628.
60. Berry DA, Cirrincione CC, Henderson IC, et al. Effects of improvements in chemotherapy on disease-free and overall survival of ER-negative, node-positive breast cancer: 20-year experience of CALGB and US Breast Intergroup. Breast Cancer Res Treat 2004; 88(suppl 1):S17 (Abstract #29).
61. Trudeau M. Optimizing adjuvant breast cancer chemotherapy: rationale for the MA.21 study. Oncology 2001; 15:7-13.
62. Sanchez P, Medina MD, Mohedano N, et al. Results from a phase II study of gemcitabine in combination with paclitaxel in metastatic breast cancer. Ann Oncol 1998; 9:16.
63. Colomer R, Llombart A, Lluch A, et al. Biweekly paclitaxel and gemcitabine in advanced breast cancer. Phase II trial and predictive value of HER2 extracellular domain (ECD). Proc Am Soc Clin Oncol 2000; 19:97a (Abstract #373).
64. Ellis GK, Livingston RB, Gralow JR, et al. Dose-dense anthracycline-based chemotherapy for node-positive breast cancer. J Clin Oncol 2002; 20:3637-3643.